Disclosure: This site earns commissions from affiliate links (Amazon, Etsy, and others) at no extra cost to you.   Full affiliate disclosure →

Updated July 2026 · 9 min read

This article was created with AI assistance.

Argatroban & Bivalirudin for HIT 2026

Part of the ICU Pharmacology Hub — browse every related guide in one place.

When a patient develops heparin-induced thrombocytopenia (HIT), you cannot give heparin — not even to flush a line. The direct thrombin inhibitors argatroban and bivalirudin become the anticoagulants of choice, and each has an organ-based reason for being picked.

Why they matter: HIT is a paradoxical, immune-mediated reaction where heparin triggers clotting and a falling platelet count. Stopping heparin isn't enough — the patient is prothrombotic and needs a non-heparin anticoagulant right away. Argatroban and bivalirudin are direct thrombin inhibitors (DTIs) that don't cross-react with HIT antibodies.

Recognizing the HIT trigger

Classic HIT shows up 5–10 days after heparin exposure (sooner with recent prior exposure) as a platelet drop of roughly 50% or more, often with new thrombosis rather than bleeding. Clinicians use the 4Ts score to gauge probability. The moment HIT is suspected, all heparin stops — IV, subcutaneous, flushes, and heparin-coated catheters — and a DTI starts. As a nurse, scrubbing every hidden heparin source is a real safety task.

Argatroban vs bivalirudin: organ-based choice

ArgatrobanBivalirudin
ClearanceHepatic (liver)Mostly enzymatic + ~20% renal
Prefer whenRenal impairment / dialysisHepatic impairment
Reduce dose inLiver dysfunctionRenal dysfunction
MonitoringaPTT (commonly)aPTT (commonly)
Half-lifeShort (~40–50 min)Very short (~25 min)

The memory hook: argatroban = liver-cleared, so use it when the kidneys are bad; bivalirudin has renal handling, so it's often favored when the liver is bad. Both have short half-lives, which is helpful because neither has a reversal agent — stopping the drip is the "reversal," and effect fades quickly.

Titration and monitoring

Both are typically titrated to a target aPTT (often around 1.5–3 times baseline, per protocol) with no bolus in HIT for argatroban in most stable patients. Check the aPTT at the protocol interval after every rate change, and don't chase a single value — trend it. Because there's no antidote, over-anticoagulation is managed by holding or reducing the infusion and letting the short half-life work.

The argatroban–INR trap. Argatroban elevates the INR on its own, independent of warfarin. When transitioning a HIT patient from argatroban to warfarin, the combined INR reads artificially high, and stopping argatroban too early based on that inflated number can leave the patient under-anticoagulated. There's a specific overlap protocol (continue argatroban until INR exceeds a higher threshold, then recheck INR after stopping). Know that your unit has a defined bridge procedure and follow it exactly — this is a classic source of error.

Nursing safety priorities

Eliminate every heparin source at initiation. Draw aPTT (or the assay your protocol specifies) on schedule and after each titration. Watch for bleeding — these are potent anticoagulants with no reversal agent, so monitor puncture sites, drains, neuro status, and hemoglobin. Track the platelet count for recovery, which helps confirm the diagnosis and guides the warfarin transition (warfarin isn't started until platelets recover). And during any argatroban-to-warfarin overlap, flag the INR interpretation issue to the team.

Bottom line: In suspected HIT, stop all heparin and start a direct thrombin inhibitor. Choose argatroban when renal function is poor (it's liver-cleared) and bivalirudin when hepatic function is poor. Titrate to aPTT, remember there's no reversal agent (rely on the short half-life), and respect the argatroban-inflated-INR trap during the warfarin bridge.

Related: heparin drip guide, protamine (heparin reversal), and ICU drip guides.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.

Get The ICU Notebook Newsletter

Clinical tools and career insights for ICU nurses. One email per week, no fluff.

Yes, send it free

No spam. Unsubscribe any time.